Next 10 |
2024-05-15 20:25:24 ET Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference Call May 15, 2024 14:05 ET Company Participants Gilmore O’Neill - Chief Executive Officer Conference Call Participants Luca Issi - RBC Capital Markets ...
2024-05-15 08:58:29 ET Summary Editas Medicine shares have underperformed the S&P 500 by over 108% in the last three years. The company has a promising pipeline and is making strides in preclinical and clinical trials. However, weak financials and the risk associated with ...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizga...
Research includes the first-ever application of AsCas12a in vivo , optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Company’s in vivo gene editing medicines pipeline CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWI...
2024-05-09 13:12:00 ET Clinical-stage biotech Editas Medicine (NASDAQ: EDIT) delivered quarterly results that fell well short of expectations on Wednesday. While one analyst trimmed her price target on the stock in response, she's still extremely bullish on its prospects. In fact, s...
2024-05-09 08:59:08 ET More on Editas Medicine Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global B...
2024-05-08 19:15:01 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for EDIT on May 8, 2024 06:25PM ET. The previous analyst recommendation was Underweight. EDIT was trading at $5.035 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-05-08 18:15:02 ET Citigroup analyst issues BUY recommendation for EDIT on May 8, 2024 04:01PM ET. The previous analyst recommendation was Buy. EDIT was trading at $5.035 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...
2024-05-08 10:57:01 ET Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Conference Call May 08, 2024, 08:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Linda Burkly - ...
2024-05-08 10:44:36 ET More on Editas Medicine Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) Editas Medicine, Inc. (EDIT) ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced ...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizga...
Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support...